Study Title: Clinical Evaluation of Scleral Contact Lenses

Screened n= 13 Enrolled n= 13 Included in Phase 1 Analysis n= 12 Included in Phase 2 Analysis n= 8

Baseline Characteristics

Table 1 - Gender and Age of Study Population for Phase 01

	Overall
N	12
Gender	
Female	7 (58.3%)
Male	5 (41.7%)
Age	
Mean	55.00
Std. Dev	6.5

Table 2 - Gender and Age of Study Population for Phase 02

	Overall			
N	8			
Gender				
Female	5 (62.5%)			
Male	3 (37.5%)			
Age				
Mean	53.90			
Std. Dev	6.1			

Outcome Measures Phase 1

Primary Outcome Measure - Contact Lens Centration

Table 3 – Decentration from Pupil Centre after 40 Minutes of Wear Descriptive Statistics (distances in millimetres– angles in degree)

		Horizontal Distance 40mins	Vertical Distance 40mins	Total Dis- tance 40mins	Angle 40mins
	N	39	39	39	39
Primary	Mean	0.480	-0.584	0.843	283
	Std-Dev		0.376	0.282	81
	N	36	36	36	36
Downgaze	Mean	0.532	-0.054	0.703	172
	Std-Dev	0.359	0.390	0.265	146

Secondary Outcome Measure - Corneal Clearance

Table 4 – Tear Layer Thickness at Contact Lens Apex Descriptive Statistics (distances in µm)

	TLT Apex 0 mins	TLT Apex 20 mins	TLT Apex 40 mins
N	43	45	44
Mean	512	470	452
Std-Dev	191	161	169

Adverse Events

Table 5 – Adverse Events

Number of participants affected	Event	Status
2	Hyperaemia	Resolved
1	Staining	Resolved

Outcome Measures Phase 2

<u>Primary Outcome Measure – Contact Lens Centration</u>

Table 6 – Overall Decentration from Pupil Centre Overall Descriptive Analysis – Phase 1 vs Phase 2

	Phase 1			Phase 2				
Total Dis- tance	Prin	Primary Downgaze Primary		Downgaze		nary	Downgaze	
tarioc	20 mins	40 mins	20 mins	40 mins	20 mins	40 mins	20 mins	40 mins
N	10	10	9	10	12	10	9	8
Mean	0.790	0.864	0.700	0.683	0.988	1.014	0.836	0.667
Std-Dev	0.279	0.263	0.292	0.148	0.225	0.283	0.240	0.279

<u>Secondary Outcome Measure – Corneal Clearance</u>

Table 7 – TLT from Contact Lens Centre - Descriptive Statistics

	TLT Apex 0 mins (µm)	TLT Apex 20 mins (µm)	TLT Apex 40 mins (µm)
N	13	13	13
Mean	307	296	272
Std-Dev	62	54	80

Adverse Events

No adverse event, device deficiency or quality complaints were reported In Phase 2.